This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: After review of the Italy, Netherlands, Canada, and Australia (INCAS) trial, we believe that some of the data presentation is confusing and possibly in error.¹ Table 1 reports that 37 patients completed 52 weeks in the 3-drug arm. The text of the "Virologic Effect" section and Figure 2 both report that 51% of these patients had plasma human immunodeficiency virus (HIV) RNA levels of less than 20 copies/mL at 52 weeks. We calculate that 51% of 37 is 19 patients. However, Table 3 reports that 18 of 40 patients in the same group had plasma HIV RNA suppression to less than 20 copies/mL throughout the entire period spanning weeks 40 to 52. If such is the case, there is a discrepancy between the number of patients in the triple-drug arm evaluable at 52 weeks, ie, 37 vs 40 patients. Presuming the correct number to be a total . . . [Full Text of this Article]

RELATED ARTICLES

A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients: The INCAS Trial
Julio S. G. Montaner, Peter Reiss, David Cooper, Stefano Vella, Marianne Harris, Brian Conway, Mark A. Wainberg, D. Smith, Patrick Robinson, David Hall, Maureen Myers, Joep M. A. Lange, and for the INCAS Study Group
JAMA. 1998;279(12):930-937.
ABSTRACT | FULL TEXT  

HIV Treatment Strategies: Planning for the Long Term
Roy M. Gulick
JAMA. 1998;279(12):957-959.
EXTRACT | FULL TEXT